|
Board of Directors’ Financial Performance Report
2011.03.15
|
|---|
|
In 2010, Daehan New Pharm Co., Ltd. reorganized its disrupted sales network and achieved a 22% sales growth, laying the foundation for a renewed leap forward while resolving past obstacles to growth, creating an opportunity for further development.
In the fourth quarter of 2010, the company disposed of approximately 6 billion KRW of doubtful accounts receivable from before 2008 through sales of accounts receivable. This was rigorously evaluated through an audit by an accounting firm between November 17 and November 29, 2010, and sold to a specialized acquiring company.
As a result, operating profit amounted to 5.8 billion KRW, up 7% year-over-year, but a loss on accounts receivable sales (-6 billion KRW), an extraordinary expense, caused a net loss of 2.7 billion KRW. While the net loss occurred temporarily due to the loss on accounts receivable sales, operating profit increased compared to the previous year. Through this disposal of doubtful accounts receivable, the company improved asset soundness and financial structure while also achieving tax reduction and securing cash liquidity.
Going forward, the company will strive for a united effort by all executives and employees to achieve sales of 100 billion KRW within the next two to three years. |


Home